IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$468.63 USD
-9.21 (-1.93%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $468.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$468.63 USD
-9.21 (-1.93%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $468.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
Zacks News
IDEXX (IDXX) Collaborates With PetDx for Canine Cancer Test
by Zacks Equity Research
Following the partnership between IDEXX (IDXX) and PetDx , the test is likely to be available later in January to all veterinary customers of IDXX in the United States and Canada.
IDEXX's (IDXX) Low LPD Sales, Rise in Expenses Dampen Growth
by Zacks Equity Research
Distributor purchasing dynamics have an impact on IDEXX's (IDXX) reported sales of CAG products.
Should iShares Russell MidCap ETF (IWR) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWR
Idexx Laboratories (IDXX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Idexx Laboratories (IDXX) closed at $661.32 in the latest trading session, marking a +0.86% move from the prior day.
IDEXX's (IDXX) Organic Growth Robust, LPD Revenues Decline
by Zacks Equity Research
IDEXX's (IDXX) global Reference Lab businesses continue to be robust driven by high same-store volume growth with strong gains across testing categories.
Idexx Laboratories (IDXX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Idexx Laboratories (IDXX) closed at $645.02 in the latest trading session, marking a +0.78% move from the prior day.
Idexx Laboratories (IDXX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Idexx Laboratories (IDXX) closed at $645.02 in the latest trading session, marking a +0.78% move from the prior day.
Idexx Laboratories (IDXX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Idexx Laboratories (IDXX) closed the most recent trading day at $596.35, moving -1.49% from the previous trading session.
Idexx Laboratories (IDXX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Idexx Laboratories (IDXX) closed at $618.55 in the latest trading session, marking a +1.16% move from the prior day.
Here's Why You Should Retain IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Investors are optimistic about IDEXX's (IDXX) better-than-expected results and continued international growth in the third quarter.
Idexx (IDXX) Down 4.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should iShares Russell MidCap Growth ETF (IWP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWP
The Zacks Analyst Blog Highlights: Walmart, Honeywell, Zoetis, Colgate-Palmolive and IDEXX Lab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walmart, Honeywell, Zoetis, Colgate-Palmolive and IDEXX Lab
Should iShares Russell MidCap ETF (IWR) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWR
Top Stock Reports for Walmart, Honeywell & Zoetis
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), Honeywell International Inc. (HON), and Zoetis Inc. (ZTS).
IDEXX (IDXX) CAG Placement Grows Globally, LPD Disappoints
by Zacks Equity Research
IDEXX' (IDXX) global Reference Lab businesses are robust driven by high same-store volume growth with strong gains across testing categories.
The Zacks Analyst Blog Highlights: Mastercard, Linde, Lam Research, Marvell Technology and IDEXX Laboratories
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, Linde, Lam Research, Marvell Technology and IDEXX Laboratories
Top Research Reports for Mastercard, Linde & Lam Research
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), Linde plc (LIN), and Lam Research Corporation (LRCX).
IDEXX (IDXX) Q3 Earnings Beat Estimates, Gross Margin Falls
by Zacks Equity Research
IDEXX's (IDXX) Q3 top line rides on strong sales at the CAG and Water businesses.
Idexx Laboratories (IDXX) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 7.98% and 2.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on Nov 2: IDXX, STE & More
by Urmimala Biswas
With the pandemic raging on, testing, vaccine and therapeutic makers are witnessing huge market adoption of their COVID-related support products in Q3.
Idexx Laboratories (IDXX) Crossed Above the 50-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?
by Zacks Equity Research
Sector ETF report for RYH
Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RYH
Should You Buy IDEXX Laboratories (IDXX) Ahead of Earnings?
by Zacks Equity Research
IDEXX Laboratories (IDXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.